CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CRISPR Therapeutics AGNASDAQ: CRSP
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $71.89M rose 22.0% year over year, ahead of the +1.6% change in trailing-twelve-month research & development. Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at -16.9% a year.
Context
- Research & development amounted to 7559.2% of revenue in FY2025, up 6643.0 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +1.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 265.33M USD
- Year-over-year change
- -17.3%
- 4-year CAGR
- -6.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 265.33M | -17.3% |
| FY2024 | 2024-12-31 | 320.65M | -17.2% |
| FY2023 | 2023-12-31 | 387.33M | -16.1% |
| FY2022 | 2022-12-31 | 461.65M | +35.6% |
| FY2021 | 2021-12-31 | 340.57M | — |
Research & Development vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 research & development of $283.28M is the 3rd highest of the 7 companies compared; the peer median is $225.71M.
- Its year-over-year change of +1.6% is the 3rd highest of 7, against a peer median of -16.2%.
- Research & development amounts to 1125.4% of revenue for CRSP, versus a peer median of 215.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $222.77M | -37.9% | -38.6% | 157.6% | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| Peer median (excluding CRSP) | $225.71M | -16.2% | -2.3% | 215.7% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 913.08M | 436K | 370M | 35M | 3.51M |
| Cost of Revenue | 101.18M | 110.25M | 130.25M | 110.25M | 232.96M |
| Gross Profit | 811.9M | (109.81M) | 239.75M | (75.25M) | (229.45M) |
| Gross Margin | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Research & Development | 340.57M | 461.65M | 387.33M | 320.65M | 265.33M |
| Selling, General & Admin | 99.69M | 102.46M | 76.16M | 72.98M | 73.54M |
| Operating Expenses | 438.38M | 563.35M | 462.29M | 391.32M | 338.87M |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| EBITDA | 397.48M | (626.33M) | (130.89M) | (343.41M) | (558.49M) |
| EBITDA Margin | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% |
| Operating Income | 373.53M | (673.16M) | (222.54M) | (466.57M) | (568.32M) |
| Operating Margin | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6M | 22.66M | 71.82M | 103.9M | (9.65M) |
| Income Before Tax | 379.53M | (650.5M) | (150.72M) | (362.67M) | (577.97M) |
| Pre-Tax Margin | 41.6% | -149197.2% | -40.7% | -1036.2% | -16466.2% |
| Income Tax Expense | 1.87M | (325K) | 2.89M | 3.59M | 3.63M |
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Net Margin | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (Basic) | 4.97 | (8.36) | (1.94) | (4.34) | (6.47) |
| EPS (Diluted) | 4.70 | (8.36) | (1.94) | (4.34) | (6.47) |
| Weighted Avg Shares | 75.95M | 77.75M | 79.22M | 84.36M | 89.93M |
| Weighted Avg Shares (Diluted) | 80.39M | 77.75M | 79.22M | 84.36M | 89.93M |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.